EBMT 2020 | Repurposing monoclonal antibodies in the face of the COVID-19 pandemic
Christian Chabannon • 1 Sep 2020
Christian Chabannon, MD, PhD, Aix Marseille Université (AMU) School of Medicine, Marseille, France, discusses the repurposing of monoclonal antibodies and other immunotherapies during the COVID-19, with the aim of modulating the hyper-immune response associated with the disease. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
Disclosures
Sanofi SA, Kite / Gilead, Novartis, Celgene / BMS, Janssen, Bellicum Pharmaceuticals, Terumo BCT: speakers bureau & advisory boards
